Bluejay Diagnostics (BJDX) Net Income towards Common Stockholders (2020 - 2026)

Bluejay Diagnostics has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$2.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 5.79% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.0 million (up 65.88% YoY) and the FY2025 annual result came in at -$6.8 million, up 67.3% from the prior year.
• Net Income towards Common Stockholders fell to -$2.0 million in Q1 2026 per BJDX's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$1.4 million in Q4 2025 and troughed at -$14.7 million in Q3 2024.
• A 5-year average of -$2.9 million and a median of -$2.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 791.77% in 2022, then soared 89.14% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$2.5 million in 2022, then climbed by 2.39% to -$2.4 million in 2023, then surged by 41.09% to -$1.4 million in 2024, then gained by 0.15% to -$1.4 million in 2025, then plunged by 41.28% to -$2.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.0 million, -$1.4 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.